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System of natriuretic peptides
Cytokines
Hormone replacement therapyCardiovascular and immune system abnormalities have been reported in females with estrogen deﬁciency.
To control these disorders in post-menopausal women, hormone replacement therapy (HRT) has been
used. Tibolone has been used as a HRT, but the effects of tibolone on the natriuretic peptide system have
not been determined. We investigated the effects of tibolone on the natriuretic peptide system and
pro-inﬂammatory cytokines in ovariectomized (OVX) rats. Female rats were divided into four groups:
SHAM, OVX, OVX treated with 17β-estradiol (OVX+E: 14 days) and OVX treated with tibolone (OVX+T:
14 days) beginning 21 days after ovariectomy. On day 35, blood was collected to determine atrial natriuretic
peptide (ANP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) levels. In addition, tissues were
collected for determining ANP, natriuretic peptide receptor type-A (NPR-A), and NPR type-C (NPR-C) gene
expression levels by RT-PCR. The cytokine levels of both IL-6 and TNF-α were increased in OVX animals. In
comparison, IL-6 and TNF-α levels were reduced in OVX+E animals. TNF-α levels were reduced similarly
in OVX+T animals, but IL-6 levels remained elevated in this group. The concentrations of ANP in the left atri-
um tissue and plasma were decreased after ovariectomy, as were ANP mRNA levels in the left atrium and
NPR-A mRNA levels in kidney. No variation in NPR-C gene expression in the kidney tissue was observed
among the groups. Tibolone and 17β-estradiol effectively increased plasma ANP and ANP mRNA levels in
the left atrium, but did not normalize renal NPR-A levels. Since HRT with tibolone normalizes plasma ANP
and serum TNF-alpha levels our results suggest that treatment with tibolone has anti-inﬂammatory effects
and could prevent cardiovascular disease in the long-term.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Atrial natriuretic peptide (ANP) plays a vital role in regulating
cardiovascular function, maintaining blood pressure and body
ﬂuid homeostasis [1]. In addition, inappropriate activation of pro-
inﬂammatory cytokines such as tumor necrosis factor-alpha (TNF-α)
and interleukin-6 (IL-6) has been recognized as an important mediator
in the development of endothelial dysfunction, cardiac hypertrophy
and heart failure in experimental animal models and humans [2–4].
Evidence fromhuman and animal studies shows that a decrease of estro-
gen levels is accompanied by inhibition of ANP gene expression [5–7], di-
minished circulating levels of ANP [6–10], and increased production ofFisiológicas, Centro de Ciências
echal Campos 1468, Vitória, ES,
3335 7340.
vier OA license.pro-inﬂammatory cytokines such as IL-6 and TNF-α [11–14]. Thus, the
impairment of the immune system and the cardiovascular system ob-
served with estradiol deﬁciency may be associated.
Indeed, recent studies have begun to elucidate the inﬂuence of ANP
on the immune system [15–17]. In mice lacking natriuretic peptide
receptor type A (NPR-A), enhanced activation of pro-inﬂammatory
cytokines is detected [18]. NPR-Ahas guanylate cyclase activity andme-
diates themajority of the biological effects of ANP [19]. In addition, ANP
binds natriuretic peptide receptor type-C (NPR-C), which does not have
guanylate cyclase activity, but removes natriuretic peptides from circu-
lation [20] and is abundantly expressed in the kidney [21]. Further
supporting a link between ANP and the immune system, ANP and its re-
ceptors are expressed by, and regulated by, immune cells [16].
Few studies have investigated the effects of hormone replacement
therapy (HRT) with estrogen on ANP and, to our knowledge, there are
no data available concerning the effect of tibolone on the natriuretic
peptide system. Tibolone, which has metabolites with estrogenic
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[3β-OH]) and progestogenic and/or androgenic effects (tibolone and
Delta(4)tibolone), may be used as an alternative to classical HRT with
estrogen and progesterone [22–24]. In order to further elucidate the ef-
fects of the tibolone, we examined how tibolone treatment affects the
natriuretic peptide system in rats.We hypothesized that tibolone treat-
ment would alter ANP synthesis, secretion, and bioavailability in circu-
lation and that a tibolone treatment that has the aforementioned effects
on the natriuretic peptide systemmay also affect levels of inﬂammatory
cytokines, such as TNF-α and IL-6, in ovariectomized rats.
Accordingly, this study was designed to evaluate whether tibolone
treatment can normalize the natriuretic peptide system and promote
a reduction in the levels of TNF-α and IL-6 in ovariectomized rats.
2. Materials and methods
2.1. Animals
Adult female Wistar rats weighing 160–180 g were obtained from
the breeding unit at the Federal University of Espírito Santo. The rats
were housed with controlled temperature (22 °C), humidity (40%)
and light cycles (12-h light/dark), and they were given water and
standard rat chow (Purina Labina, SP-Brazil) ad libitum. The proce-
dures were carried out in compliance with the guidelines for the eth-
ical use of animals in scientiﬁc research as stated by the Federation of
the Brazilian Society of Experimental Biology and were approved by
the Ethics Committee for Animal Use at the Federal University of
Espírito Santo (014/2008). Ketamine (70 mg/kg) and xylazine
(10 mg/kg) were injected intraperitoneally to anesthetize the rats
prior to all surgical procedures.
Four groups of female rats were studied: sham-operated females
(SHAM); ovariectomized (OVX); OVX treated with 17β-estradiol
(OVX+E: 0.5 μg/kg/day; Sigma Chemical Co., St. Louis, MO, USA) or
OVX treated with tibolone (OVX+T: 1.5 mg/kg/day). Tibolone was
given by gavage, and 17β-estradiol was injected subcutaneously.
The rats were treated for 14 days beginning 21 days after bilateral
ovariectomy.
2.2. Measurement of arterial blood pressure (BP) and heart rate (HR)
Mean arterial pressure and heart rate were determined by direct
measurement in each group at the end of treatment. Forty-eight
hours after the end of the treatment, BP and HR at rest were mea-
sured. For this procedure, on the day before the measurement was
taken, a catheter ﬁlled with saline (PE-50) was inserted into the left
femoral artery while the subject was under anesthesia (ketamine
70 mg/kg, xylazine 10 mg/kg). The free end of the catheter was exte-
riorized at the cervical dorsal area. For the BP measurement, the arte-
rial catheter was attached to a 40-cm polyethylene catheter during
the 40 min recording period. BP measurements were obtained in
quiet, conscious rats that had complete freedom to move throughout
the cage. The BP was recorded by a pressure transducer coupled to a
MP-100 System Guide (model MP100-CE; Biopac Systems, Santa
Barbara, CA, USA). The HR was calculated instantaneously from the
intervals of pressure pulses.
2.3. Collection of serum, plasma and tissues
After measuring BP and HR, the females were decapitated, and 5 ml
of blood was collected in pre-chilled tubes containing heparin sulfate
and protease inhibitors: 10−5 mol/l ethylenediaminetetraacetic acid
(EDTA), 10−5 mol/l phenylmethylsulfonyl ﬂuoride (PMSF), and
0.5×10−5 mol/l pepstatin A (all purchased from Sigma, St. Louis, MO,
USA), to obtain plasma. Blood samples were also collected in empty
tubes to obtain serum. The blood samples were centrifuged at 4 °C
and 2500 rpm (Eppendorf, Hamburg, Germany) for 15 min. Plasmaand serumwere stored at−80 °C. The uterus, atrium, ventricle and kid-
neys were removed, weighed, frozen in liquid nitrogen and stored at−
80 °C.
2.4. Levels of cytokines and ANP
The levels of IL-6 and TNF-α in serum were determined using
commercial enzyme-linked immunosorbent assay (ELISA) kits
according to the manufacturer's instructions (Invitrogen-BioSource
International).
The level of ANP was determined by performing a double-
antibody radioimmunoassay (RIA) as described by Gutkowska et al.
[25]. The plasma was thawed and centrifuged for 5 min at 19,400×g
and 4 °C, and ANP was extracted using Sep-Pak C18 columns (Waters
Associates, Milford, MA, USA). The columnswere activated with 8 ml of
acetonitrile and washed with 8 ml of 0.2% ammonium acetate, pH 4.0.
Afterward, 1 ml of plasma was infused into the column followed by
5 ml of 0.2% ammonium acetate. Finally, the absorbed ANP was eluted
with 3 ml of 60% acetonitrile in 0.2% ammonium acetate, evaporated
(Speed-Vac, Eppendorf, Hamburg, Germany) and stored at−20 °C for
quantiﬁcation by RIA.
To measure the ANP concentrations in the atrial tissue, each half of
the right (RA) and left atria (LA) were thawed and placed in a tube
ﬁlled with 0.1 M acetic acid and protease inhibitors (10−5 M EDTA,
10−5 M PMSF and 0.5×10−5 M pepstatin A, all purchased from
Sigma). The samples were then homogenized and centrifuged at
20,000×g for 30 min at 4 °C, and the supernatant was diluted (ﬁnal
dilution: 1:2000) in phosphate buffer (0.01 mol/l sodium phosphate,
0.14 mmol/l bovine serum albumin, 0.1% Triton X-100, 0.1 mol/l NaCl
and 0.01% sodium azide at pH 7.4). The ANP levels were measured by
RIA as previously described by Gutkowska et al. [25] using a speciﬁc
antibody that was donated by Jolanta Gutkowska. All of the samples
were measured in the same assay, and the intra-assay coefﬁcient of
variation was b10%. The protein content of the tissue was determined
using the Bradford method [26].
2.5. Gene expression of ANP, NPR-A and NPR-C
Total mRNA was extracted from the atria and kidneys by a guani-
dine isothiocyanate method previously described by Chomczynski
and Sacchi [27]. The mRNA expression levels of ANP and its receptors
(NPR-A and NPR-C) were determined by real-time PCR. The gene ex-
pression of ANP was evaluated in the RA and LA, and NPR-A and
NPR-C expression levels were determined in the right kidney. cDNA
was synthesized by the reverse transcription of mRNA. For this pro-
cess, 1 μl of mRNA from each sample was mixed in plastic tubes
with a solution containing the following compounds: diethyl
pyrocarbonate water (DEPC), the reverse primer of the target gene
(ANP, NPR-A or NPR-C) or the reverse primer of the housekeeping
gene (ribosomal subunit s26), oligo dT, triphosphate deoxyribonucle-
otide (dNTP), dithiothreitol (DTT), speciﬁc buffer (10×) and a solu-
tion containing the Moloney murine leukemia virus (MMLV)
reverse transcriptase enzyme, according to the manufacturer's guide-
lines (Invitrogen, CA, USA). After this process, the plastic tubes were
heated to 40 °C for 60 min. After reaching room temperature, the
tubes were stored at −20 °C.
For the atria, the samples were subjected to DNAse treatment
prior to reverse transcription. The DNase treatment was performed
by mixing 0.5 μg of total mRNA from the atria with 4 μl of water
and 1 μl of buffer containing DNAse (1:1). This mixture was incubat-
ed for 15 min at room temperature. After the incubation period, EDTA
was added to stop the reaction. The samples were then heated to
65 °C for 10 min.
After synthesizing the cDNA, PCR was performed to amplify the
cDNA for ANP, NPR-A and NPR-C, using speciﬁc primers (ANP:
5′-GGA TTT CAA GAA CCT GCT AGA-3′ and 5′-CTT CAT CGG TCT GCT
Table 1
Body and organ weights and organ weight/body weight ratio in the sham-operated (SHAM), ovariectomized (OVX), and OVX rats treated with 17β-estradiol (OVX+E) or tibolone
(OVX+T).
Variable SHAM OVX OVX+E OVX+T
Body weight, g 220±5 249±6⁎⁎ 217±8†† 214±4††
Uterus, mg 428.3±38.9 88.4±3.6⁎⁎ 427.5±68.2†† 299.8±15.9⁎⁎††
Uterus/body weight, mg/g 1.9±0.2 0.4±0.1⁎⁎ 2.1±0.1†† 1.5±0.1⁎††
Right atrium, mg 16.1±1.3 18.8±1.8 14.1±1.2 16.6±1.7
Right atrium/body weight, mg/g 0.072±0.010 0.076±0.009 0.065±0.012 0.077±0.010
Left atrium, mg 25.1±2.2 29.1±2.6 19.9±1.1 22.0±2.0
Left atrium/body weight, mg/g 0.11±0.01 0.12±0.02 0.09±0.02 0.10±0.01
Right ventricle, mg 134.8±9.9 150.8±9.4 146.0±9.8 124.6±9.9
Right ventricle/body weight, mg/g 0.61±0.03 0.61±0.03 0.67±0.04 0.58±0.03
Left ventricle, mg 490.4±33.5 495.2±26.9 430.6±33.0 455.7±26.9
Left ventricle/body weight, mg/g 2.23±0.07 2.10±0.06 2.01±0.04 2.13±0.05
Data are expressed as mean±SEM (n=8 animals per group).
⁎⁎ Pb0.01.
⁎ Pb0.05 vs. SHAM.
†† Pb0.01 vs. OVX.
Fig 1. The effects of ovariectomy and 17β-estradiol or tibolone treatment on the level
of ANP in the plasma. Shown are the ANP levels from sham-operated (SHAM), ovariec-
tomized (OVX), and ovariectomized rats treated with 17β-estradiol (OVX+E) or
tibolone (OVX+T). n=7 animals per group. *Pb0.05 vs. SHAM; †Pb0.05 vs. OVX.
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5′-AGA TGT AGA TAA CTC TGC CCT TTC G-3′; NPR-C: 5′-CCT ACA
ATT TCG ACG AGA CCA AA-3′ and 5′-ACT CGC TCA CTG CCC TGG
ATG TA-3′).
For this procedure, 2 μl of cDNA was added to wells of real-time
PCR plates, followed by 1.5 μl of sense primer (1 pmol/μl), 1.5 μl of
anti-sense primer (1 pmol/μl), 10 μl of Power SYBR Green PCR Master
Mix (Applied Biosystems, Warrington, UK) and 5 μl of DEPC water.
Afterward, the plates were sealed and ampliﬁed in the thermocycler
(ABI Prism 7000 SDS; Applied Biosystems, Warrington, UK) using
the following cycles: [stage 1], a cycle of 52 °C/2 min; [stage 2], a
cycle of 95 °C/10 min; [stage 3], 40 cycles of 95 °C/0.15 min and
50 °C/1 min.
2.6. Data analysis
Data are expressed as the mean±standard error of mean (SEM),
and the statistical analysis was performed using GraphPad Prism 5.
Data were compared using one-way ANOVA followed by Newman–
Keuls post hoc test. Data were considered statistically signiﬁcant if
Pb0.05.
3. Results
3.1. The effects of OVX and tibolone on physiological parameters, blood
pressure and heart rate
Baseline physiological parameters in SHAM and OVX animals and
the effects of HRT are reported in Table 1. Ovariectomy led to increased
body weight (BW); however, the treatment with 17β-estradiol
(OVX+E) or tibolone (OVX+T) normalized BW (Pb0.01). The uterus
weight aswell as the uterusweight-to-BW ratiowere largely decreased
in the OVX groups (Pb0.01) indicating the efﬁciency of ovariectomy.
However, in the OVX+T group, there was an increase in the uterus
weight-to-BW ratio compared to the OVX group, but did not return to
normal when compared to the SHAM group. This ﬁnding is different
from what occur in the OVX+E group when the uterus weight-to-BW
ratio returned to normal values. Ovariectomy or any of the HRT used
in the present study did not alter the weight-to-BW ratio of the heart
chambers (Table 1).
Mean arterial pressure (MAP) and heart rate (HR)were not different
in the SHAMandOVX groups (105±2 vs. 98±1 mmHg and 373±7 vs.
372±6 beats per min, respectively). In addition, administration of
17β-estradiol or tibolone, respectively, to ovariectomized rats did not
change MAP (101±2 and 103±3 mmHg) or HR (368±5 and 364±
9 beats per min).3.2. Levels of ANP and NPR in response to ovariectomy and 17β-estradiol
or tibolone treatment
In the vehicle-treated OVX rats, the plasma ANP concentrations
(92.50±19.50 pg/ml) were lower than in the SHAM group
(263.30±53.30 pg/ml, Pb0.05). Treatment with 17β-estradiol or
tibolone increased plasma levels of ANP in OVX rats (OVX+E:
247.30±29.90; OVX+T: 285.70±60.40 pg/ml, Pb0.05 vs. OVX)
(Fig. 1).
RIA revealed that ovariectomy and estradiol treatment decreased
and increased ANP concentrations, respectively, in the left atrium
but not the right atrium (Fig. 2A). The ANP concentration in the left
atrium decreased from 5.68±0.35 μg/mg protein in the SHAM
group to 3.48±0.40 μg/mg protein in the OVX group (Pb0.05). How-
ever, in the OVX+E group, the ANP levels in the left atrium increased
to 6.48±0.97 mg/mg protein (Pb0.05), which was similar to the
levels observed in the SHAM group. On the other hand, the ANP levels
in the left atrium did not return to levels similar to the SHAM group in
the OVX+T group (3.59±0.25 mg/mg protein, Pb0.05 vs. SHAM). As
shown in Fig. 2B, changes in the ANP mRNA levels were associated
with increased plasma ANP levels. The OVX group had lower ANP
mRNA levels in the left atrium (40.00±10.10 AU) compared with
the SHAM group (91.30±4.40) indicating that lower levels of ANP
synthesis were occurring in the OVX group. 17β-estradiol or tibolone
treatment induced a large increase in the ANP gene expression in the
left atrium of ovariectomized rats (OVX+E: 122.30±12.00; OVX+T:
167.90±25.70 AU, Pb0.01 vs. OVX).
Fig. 2. (A) Effect of 17β-estradiol (OVX+E) or tibolone (OVX+T) treatment on ANP
concentration in the right (RA) and left (LA) atria. (B) ANP gene expression in the atri-
um. The expression of ANP was examined at the mRNA level in both the right and left
atria following 17β-estradiol or tibolone treatment for 14 days. n=7 animals per
group. **Pb0.01 and *Pb0.05 vs. SHAM; ††Pb0.01 vs. OVX.
Fig. 3. Renal mRNA expression of NPR. mRNA expression of NPR-A (A) and NPR-C (B)
normalized by s26 mRNA levels (arbitrary units) in the kidneys after 17β-estradiol
(OVX+E) or tibolone (OVX+T) treatment for 14 days. n=7 animals per group.
**Pb0.01 vs. SHAM.
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compared using RT-PCR. The kidneys from the ovariectomized rats
had lower NPR-A mRNA expression (0.68±0.11 AU) compared to
the SHAM group (12.00±5.20 AU). On the other hand, neither
17β-estradiol nor tibolone treatment normalized the expression of
NPR-A in the ovariectomized females (OVX+E: 0.92±0.28 and
OVX+T: 2.04±1.04 AU) (Fig. 3A). No variation in NPR-C gene ex-
pression in the kidney tissue was observed among the groups
(Fig. 3B).
3.3. Pro-inﬂammatory cytokine levels in response to ovariectomy and
17β-Estradiol or tibolone treatment
Fig. 4 shows the average level of IL-6 (A) and TNF-α (B) in the
serum of rats from every group. Ovariectomy resulted in a signiﬁcant
elevation of IL-6 and TNF-α levels (IL-6: 32.80±5.00 and TNF-α:
31.00±5.00 pg/ml) compared with the SHAM group (IL-6: 19.30±
6.00 and TNF-α: 20.30±2.00 pg/ml). Treatment with 17β-estradiol
decreased the IL-6 and TNF-α levels in the serum of the ovariecto-
mized rats (IL-6: 20.00±3.00 and TNF-α: 17.60±2.00 pg/ml,
Pb0.01 vs. SHAM). However, tibolone treatment in the ovariecto-
mized rats (OVX+T) decreased TNF-α levels but not IL-6 levels
(34.40±2.80) in the serum compared to the OVX group (17.60±
2.00 pg/ml, Pb0.01 vs. OVX).
4. Discussion
Tibolone may be useful as an alternative to classical HRT with es-
trogen and progesterone. However, the effects of tibolone on the na-
triuretic peptide system have not been elucidated. The present study
demonstrated that decreased ANP levels in estrogen-deﬁcient femaleFig. 4. The effects of rat ovariectomy and 17β-estradiol or tibolone treatment on serum
levels of IL-6 (A) and TNF-α (B). The results are presented from samples obtained from
sham-operated (SHAM), ovariectomized (OVX), and ovariectomized rats treated with
17β-estradiol (OVX+E) or tibolone (OVX+T). n=7 animals per group. **Pb0.01 vs.
SHAM; ††Pb0.01 vs. OVX.
59A.R.S. Medeiros et al. / Regulatory Peptides 179 (2012) 55–60rats were accompanied by an increase in circulating levels of IL-6 and
TNF-α. Plasma ANP levels were increased and serum TNF-α levels
were decreased in tibolone treated OVX rats.
Although ANP is a hormone that promotes acute vasodilation, na-
triuresis, and diuresis, with a consequent reduction in blood pressure
[28], the reduction in plasma levels of ANP in OVX females in our
study did not lead to hemodynamic changes 35 d after estrogen dep-
rivation. Previous studies have shown that, in both women and ani-
mals, HRT with estradiol caused plasma ANP levels to rise while BP
values remained unchanged [6,9,10,29]. The role of ANP is more evi-
dent when there is hypertension. HRT with 17β-estradiol has been
reported to reduce BP in spontaneously hypertensive rats, with a con-
comitant increase in the synthesis and release of ANP, suggesting that
the natriuretic peptide system is modulated by 17β-estradiol [10].
In the current study, ovariectomy led to a reduction in plasma ANP
concentrations and renal NPR-A mRNA levels, without affecting the
expression of NPR-C. The lower level of plasma ANP observed in
OVX rats in the absence of a change in NPR-C clearance receptors sug-
gests that ANP synthesis was impaired in the OVX group. Tibolone
treatment induced a large increase in ANP gene expression in the
left atrium as well as a large increase in plasma ANP levels in OVX
rats. However, the ANP levels in the left atrium were not normalized
by the tibolone treatment. Given that androgens have previously
been shown to increase ANP release [30], a likely mechanism of ac-
tion of tibolone is that an androgen metabolite of tibolone is respon-
sible for the increases in ANP levels observed in our tibolone treated
rats. Our data also suggest that tibolone itself can induce ANP release,
because tibolone treatment did not normalize ANP concentration in
the left atrium. The effects of tibolone on the formation of the atrial
granules and on the secretion of ANP need to be elucidated.
Our ﬁndings with respect to ANP receptor expression in the kidney
demonstrated that tibolone treatment did not normalize renal NPR-A
mRNA levels in OVX animals, while the increased plasma ANP levels
thatwere observed could potentially lead to an improvement in ANPbi-
ological activity, since NPR-A is expressed in other tissues, such as adi-
pose tissues [7] and immune cells [16]. Thus, we believe that ANP
synthesis was normalized in our OVX+T group due an increase ANP
mRNA and plasma ANP levels without a change in renal clearance re-
ceptors. If neutral endopeptidase 24.11 (NEP) [31] is involved in ANP
degradation, it could potentially play a role in the increased ANP ob-
served in tibolone- and 17β-estradiol-treated rats. However, this possi-
bility is sustained by a prior study reporting that estrogen did not
signiﬁcantly affect NEP activity in the renal cortex and medulla of fe-
male rats [32].
Our results also showed that OVX females had increased serum
levels of pro-inﬂammatory cytokines (IL-6 and TNF-α) and low plasma
levels of ANP. Few studies have examined the actions of tibolone on
the immune system, and the information we do have regarding the
inﬂuence of this drug on pro-inﬂammatory cytokines is conﬂicting.
One study showed that HRT with tibolone for 2 months in post-
menopausal women did not decrease TNF-α, IL-4, IL-10, or IL-2 levels,
though it did reduce bone resorption [12]. In contrast, another study
reported that tibolone had a beneﬁcial effect on inﬂammation in
post-menopausal women, reducing TNF-α levels but not IL-6 levels
[33]. Here, we also found that tibolone reduced TNF-α levelswithout af-
fecting serum levels of IL-6 in female rats,whereas estrogen reduced the
levels of both cytokines.We further speculate that plasma ANP, in addi-
tion to its known cardiovascular effects, may also normalize levels of
pro-inﬂammatory cytokines. Our observations are consistent with pre-
vious reports indicating that ANP-induced cyclic GMP signaling can
suppress the release TNF-α in vitro [16,34] and in vivo [17,35] via inhi-
bition of NF-kβ activity.
The differing responses induced by tibolone versus estrogen in our
study may be attributable to tibolone metabolites acting on other recep-
tors [22–24], in addition to the estrogen receptor. Tibolone's three
main metabolites, 3α-hydroxytibolone, 3β-hydroxytibolone, and theDelta(4)tibolone isomer, possess different afﬁnities. The hydroxytibolone
metabolites bind to estrogen receptors, triggering estrogen-like re-
sponses, whereas the Delta(4)tibolone isomer has a high afﬁnity for pro-
gesterone and androgen receptors (22). Therefore, relative to estrogen
which binds selectively to estrogen receptors, tibolone may produce
more complex effects via the actions of at least one of its metabolites
on these other receptors.
In conclusion, the present study demonstrated that estrogen deﬁ-
ciency in OVX rats impaired the natriuretic peptide system, which
may have contributed to the elevated concentrations of inﬂammatory
cytokines observed in this experimental model. We showed for the
ﬁrst time the inﬂuence of tibolone on the natriuretic peptide system
in OVX rats. Our experiments demonstrated that tibolone possesses
anti-inﬂammatory actions in vivo, as evidenced by increased ANP
levels and decreased TNF-α levels. These ﬁndings may have impor-
tant implications for the treatment of post-menopausal cardiovascu-
lar and immunological complications.
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